PMID- 27872179
OWN - NLM
STAT- MEDLINE
DCOM- 20180102
LR  - 20220419
IS  - 1708-8283 (Electronic)
IS  - 0883-0738 (Linking)
VI  - 32
IP  - 2
DP  - 2017 Feb
TI  - Anti- N-Methyl-d-Aspartate (NMDA) Receptor Encephalitis.
PG  - 243-245
LID - 10.1177/0883073816675557 [doi]
AB  - Anti- N-methyl-d-aspartate receptor (NMDAR) encephalitis has been shown to be a 
      treatable form of autoimmune encephalitis, but there remains no standardized 
      approach to immunotherapy. We designed an anonymous survey sent to members of the 
      Child Neurology Society to identify the current practices among child 
      neurologists. A total of 151 pediatric neurologists responded to the survey. With 
      these responses we were able to highlight areas of practice uniformity, including 
      first-line treatment with intravenous immunoglobulin and intravenous 
      methylprednisone and initiation of disease-modifying therapy with rituximab 
      alone. The survey also identifies existing gaps in knowledge, specifically, when 
      to add disease-modifying therapy and how long to continue therapy. We propose 
      that the areas of agreement can be used as a step toward establishing standard 
      treatment guidelines and research protocols directed at evidence-based clinical 
      trials.
FAU - Kahn, Ilana
AU  - Kahn I
AD  - 1 Department of Neurology, Children's National Health System, NW, Washington, DC, 
      USA.
FAU - Helman, Guy
AU  - Helman G
AD  - 1 Department of Neurology, Children's National Health System, NW, Washington, DC, 
      USA.
AD  - 2 Children's Research Institute, NW, Washington, DC, USA.
FAU - Vanderver, Adeline
AU  - Vanderver A
AD  - 1 Department of Neurology, Children's National Health System, NW, Washington, DC, 
      USA.
AD  - 2 Children's Research Institute, NW, Washington, DC, USA.
FAU - Wells, Elizabeth
AU  - Wells E
AD  - 1 Department of Neurology, Children's National Health System, NW, Washington, DC, 
      USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161122
PL  - United States
TA  - J Child Neurol
JT  - Journal of child neurology
JID - 8606714
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Anti-N-Methyl-D-Aspartate Receptor Encephalitis/*therapy
MH  - Child
MH  - Clinical Protocols
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Immunologic Factors/therapeutic use
MH  - Immunotherapy
MH  - Neurologists
MH  - Pediatricians
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - anti-NMDA receptor encephalitis
OT  - immunotherapy
OT  - pediatric neurology
OT  - rituximab
OT  - treatment protocol
EDAT- 2016/11/23 06:00
MHDA- 2018/01/03 06:00
CRDT- 2016/11/23 06:00
PHST- 2016/11/23 06:00 [pubmed]
PHST- 2018/01/03 06:00 [medline]
PHST- 2016/11/23 06:00 [entrez]
AID - 0883073816675557 [pii]
AID - 10.1177/0883073816675557 [doi]
PST - ppublish
SO  - J Child Neurol. 2017 Feb;32(2):243-245. doi: 10.1177/0883073816675557. Epub 2016 
      Nov 22.